Top

Rheumatology International

Published in:

01-07-2014 | Letter to the Editor

Interleukin-21, a potential diagnostic and therapeutic target for systemic lupus erythematosus

Authors: Yong He, Cheng Huang, Lei Zhang, Xiong-wen Lv, Jun Li

Published in: Rheumatology International | Issue 7/2014

Excerpt

Dear Editor, …

Pan HF, Wu GC, Fan YG, Leng RX, Peng H, Zhou M, Li BZ, Zhu Y, Tao JH, Li XP, Ye DQ (2013) Decreased serum level of IL-21 in new-onset systemic lupus erythematosus patients. Rheumatol Int 33(9):2337–2342. doi:10.1007/s00296-013-2724-1

Li J, Pan HF, Cen H, Tian J, Ma Y, Tao JH, Ye DQ (2011) Interleukin-21 as a potential therapeutic target for systemic lupus erythematosus. Mol Biol Rep 38(6):4077–4081PubMedCrossRef

Nguyen V, Luzina I, Rus H, Tegla C, Chen C, Rus V (2012) IL-21 promotes lupus-like disease in chronic graft-versus-host disease through both CD4 T cell- and B cell-intrinsic mechanisms. J Immunol 189(2):1081–1093PubMedCentralPubMedCrossRef

Bubier JA, Sproule TJ, Foreman O, Spolski R, Shaffer DJ, Morse HC 3rd, Leonard WJ, Roopenian DC (2009) A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci USA 106(5):1518–1523PubMedCentralPubMedCrossRef

Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K (2007) IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R. Fc reduces disease progression. J Immunol 178(6):3822–3830PubMedCrossRef

Rankin AL, Guay H, Herber D, Bertino SA, Duzanski TA, Carrier Y, Keegan S, Senices M, Stedman N, Ryan M, Bloom L, Medley Q, Collins M, Nickerson-Nutter C, Craft J, Young D, Dunussi-Joannopoulos K (2012) IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J Immunol 188(4):1656–1667PubMedCentralPubMedCrossRef

Mitoma H, Horiuchi T, Kimoto Y, Tsukamoto H, Uchino A, Tamimoto Y, Miyagi Y, Harada M (2005) Decreased expression of interleukin-21 receptor on peripheral B lymphocytes in systemic lupus erythematosus. Int J Mol Med 16(4):609–615PubMed

Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW (2010) Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol 30(1):45–52PubMed

Dolff S, Abdulahad WH, Westra J, Doornbos-van der Meer B, Limburg PC, Kallenberg CG, Bijl M (2011) Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Res Ther 13(5):R157PubMedCentralPubMedCrossRef

10.

Terrier B, Costedoat-Chalumeau N, Garrido M, Geri G, Rosenzwajg M, Musset L, Klatzmann D, Saadoun D, Cacoub P (2012) Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol 39(9):1819–1828PubMedCrossRef

11.

Nakou M, Papadimitraki ED, Fanouriakis A, Bertsias GK, Choulaki C, Goulidaki N, Sidiropoulos P, Boumpas DT (2013) Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells. Clin Exp Rheumatol 31(2):172–179PubMed

12.

Ding L, Wang S, Chen GM, Leng RX, Pan HF, Ye DQ (2012) A single nucleotide polymorphism of IL-21 gene is associated with systemic lupus erythematosus in a Chinese population. Inflammation 35(6):1781–1785PubMedCrossRef

13.

Yu B, Guan M, Peng Y, Shao Y, Zhang C, Yue X, Zhang J, Yang H, Zou H, Ye W, Wan J, Zhang W (2011) Copy number variations of interleukin-17F, interleukin-21, and interleukin-22 are associated with systemic lupus erythematosus. Arthritis Rheum 63(11):3487–3492PubMedCrossRef

14.

Sawalha AH, Kaufman KM, Kelly JA, Adler AJ, Aberle T, Kilpatrick J, Wakeland EK, Li QZ, Wandstrat AE, Karp DR, James JA, Merrill JT, Lipsky P, Harley JB (2008) Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 67(4):458–461PubMedCrossRef

Title: Interleukin-21, a potential diagnostic and therapeutic target for systemic lupus erythematosus
Authors: Yong He
Cheng Huang
Lei Zhang
Xiong-wen Lv
Jun Li
Publication date: 01-07-2014
Publisher: Springer Berlin Heidelberg
Published in: Rheumatology International / Issue 7/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-013-2860-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Interleukin-21, a potential diagnostic and therapeutic target for systemic lupus erythematosus

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2014

Erratum to: Refractory urticaria in adult-onset Still’s disease

Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease

Exercise therapy for spondyloarthritis: a systematic review

Social persuasion in rheumatology: a randomized trial of testimonials on television in the rheumatology clinic waiting room to increase attendance for multidisciplinary education

Intraarticular corticosteroids in refractory childhood Lyme arthritis

Reliability and validity of the Spanish version of the Pittsburgh Sleep Quality Index (PSQI) in patients with fibromyalgia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page